nach oben

Osteoporosis International

Erschienen in:

02.05.2020 | Original Article

Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial

verfasst von: G. Cai, H. I. Keen, L. V. Host, D. Aitken, L. L. Laslett, T. Winzenberg, A. E. Wluka, D. Black, G. Jones

Erschienen in: Osteoporosis International | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study evaluated whether zoledronic acid (ZA) inhibited the progression of abdominal aortic calcification (AAC) over 3 years in 502 postmenopausal women with osteoporosis. AAC progressed in a similar proportion of participants in the ZA (29%) and placebo (31%) groups, suggesting no effect of ZA on AAC progression.

Introduction

Bisphosphonate use is associated with reduced risk of all-cause mortality and cardiovascular events. The underlying mechanisms are uncertain but may include effects on vascular calcification. This study aimed to evaluate the effect of zoledronic acid (ZA) on abdominal aortic calcification (AAC) in postmenopausal women with osteoporosis.

Methods

This was a post hoc analysis of the HORIZON Pivotal Fracture Trial that included 502 postmenopausal women (mean age 72.5 years) with osteoporosis (234 received ZA and 268 placebo). AAC scores (range, 0–8) were assessed from paired spine X-rays at baseline and after 3 years. Progression of AAC was defined as any increase in AAC score. The association between change in hip and femoral neck bone mineral density and change in AAC score was also assessed.

Results

At baseline, 292 (58.2%) participants had AAC (i.e., AAC score > 0), with AAC scores similar in the two intervention groups (median [interquartile range], 1 [0 to 2] for both; p = 0.98). Over 3 years, AAC progressed in a similar proportion of participants in both groups (ZA 29% and placebo 31%; p = 0.64). Change in bone mineral density and change in AAC score were not correlated.

Conclusion

Once-yearly zoledronic acid did not affect progression of AAC over 3 years in postmenopausal women with osteoporosis.

Trial registration

ClinicalTrials.gov identifier: NCT00049829

Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMed

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407–2416PubMed

Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMed

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD (2019) Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res 35:20–27. https://doi.org/10.1002/jbmr.3860CrossRefPubMed

Grove EL, Abrahamsen B, Vestergaard P (2013) Heart failure in patients treated with bisphosphonates. J Intern Med 274:342–350PubMed

Kang JH, Keller JJ, Lin HC (2013) Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 24:271–277PubMed

Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colon-Emeric CS (2013) Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res 28:984–991PubMed

Demer LL, Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117:2938–2948PubMedPubMedCentral

Chow JT, Khosla S, Melton LJ 3rd, Atkinson EJ, Camp JJ, Kearns AE (2008) Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res 23:1601–1612PubMedPubMedCentral

10.

Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246–4253PubMed

11.

Hak AE, Pols Huibert AP, van Hemert AM, Hofman A, Witteman Jacqueline CM (2000) Progression of aortic calcification is associated with metacarpal bone loss during menopause. Arterioscler Thromb Vasc Biol 20:1926–1931PubMed

12.

Kiel D, Kauppila L, Cupples L, Hannan M, O'donnell C, Wilson P (2001) Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham heart study. Calcif Tissue Int 68:271–276PubMed

13.

Rubin MR, Silverberg SJ (2004) Vascular calcification and osteoporosis—the nature of the nexus. J Clin Endocrinol Metab 89:4243–4245PubMed

14.

Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617–625PubMedPubMedCentral

15.

Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577–1583PubMed

16.

Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915PubMed

17.

Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824PubMed

18.

Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538PubMed

19.

Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Investig 1:12–18

20.

Karwowski W, Naumnik B, Szczepanski M, Mysliwiec M (2012) The mechanism of vascular calcification - a systematic review. Med Sci Monit 18:RA1–R11PubMedPubMedCentral

21.

Cozzolino M, Dusso AS, Slatopolsky E (2001) Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12:2511–2516PubMed

22.

Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 100:2168–2176PubMed

23.

Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B (2009) Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 602:124–131PubMed

24.

Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215–222PubMed

25.

Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59–64PubMed

26.

Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241–247PubMed

27.

Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688PubMed

28.

Okamoto M, Yamanaka S, Yoshimoto W, Shigematsu T (2014) Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transp Secur 2014:269613

29.

Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, Bravo J, Burgos D, Monegal A, Muxí A, García S (2010) Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 89:1476–1481PubMed

30.

Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57–68PubMed

31.

Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16:184–190PubMed

32.

Synetos A, Toutouzas K, Drakopoulou M, Koutagiar I, Benetos G, Kotronias R, Anousakis-Vlachochristou N, Latsios G, Karanasos A, Agrogiannis G, Metaxas M, Stathogiannis K, Papanikolaou A, Georgakopoulos A, Pianou N, Tsiamis E, Patsouris E, Papalois A, Cokkinos D, Anagnostopoulos C, Tousoulis D (2018) Inhibition of aortic valve calcification by local delivery of zoledronic acid-an experimental study. J Cardiovasc Transl Res 11:192–200PubMed

33.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMed

34.

Schousboe JT, Wilson KE, Hangartner TN (2007) Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. PLoS One 2:e715PubMedPubMedCentral

35.

Bolland MJ, Wang TK, van Pelt NC, Horne AM, Mason BH, Ames RW, Grey AB, Ruygrok PN, Gamble GD, Reid IR (2010) Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res 25:505–512PubMed

36.

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMed

37.

Mansueto P, Vitale G, Seidita A, Guarneri F, Pepe I, Rinollo C, Di Rosa S, Rini G, Cillari E, Di Fede G (2011) Mevalonate pathway: role of bisphosphonates and statins. Acta Medica Mediterranea 27:85–95

38.

Ye Y, Mou Y, Bai B, Li L, Chen GP, Hu SJ (2010) Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Int J Biochem Cell Biol 42:2056–2064PubMed

39.

Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, DellʼOro R, Grassi G, Sega R, Mancia G (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27:2458–2464PubMed

40.

Galluzzo S, Santini D, Vincenzi B, Caccamo N, Meraviglia F, Salerno A, Dieli F, Tonini G (2007) Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 11:941–954PubMed

41.

Hamid T, Prabhu SD (2017) Immunomodulation is the key to cardiac repair. Circ Res 120:1530–1532PubMedPubMedCentral

42.

Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897–907PubMed

43.

Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697–711PubMedPubMedCentral

44.

Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, Custodio MR, Batista DG, Jorgetti V, Moyses RM (2007) Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71:1262–1270PubMed

45.

Pirmohamed M (2000) Commentary—bisphosphonates and calcium homoeostasis. Postgrad Med J 76:418–419PubMedPubMedCentral

Titel: Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
verfasst von: G. Cai
H. I. Keen
L. V. Host
D. Aitken
L. L. Laslett
T. Winzenberg
A. E. Wluka
D. Black
G. Jones
Publikationsdatum: 02.05.2020
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 9/2020
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05430-z

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial